IL17A and asthma: Ongoing phase II clinical trials are currently evaluating the efficacy and safety of a fully human IL-17A-specific monoclonal antibody (secukinumab), as well as of a human IL-17-receptor-specific monoclonal antibody (brodalumab), in patients with severe asthma that is not adequately controlled by inhaled corticosteroids and long-acting β2-adrenergic receptor agonists [16].